Not a good 6 months for the company, but boy, have a look at the "Resources and Reserves Statement", how can you not get excited about these figures!
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling